All In Biotech

Drug Trial Radar · NCT04999761

AB122 Platform Study

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

917

Planned (sponsor's estimate)

Start

Jun 1, 2021

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Taiho Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

Conditions

  • Advanced or Metastatic Solid Tumor
  • Pancreatic Ductal Adenocarcinoma
  • Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Gastric Cancer
  • Alveolar Soft Part Sarcoma
  • Esophageal Cancer
  • Head and Neck Cancer
  • Biliary Tract Cancer

Interventions

  • AB122Drug

    AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.

  • AB122Drug

    AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

  • TAS-116Drug

    TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

  • TAS-120Drug

    TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

  • TAS-115Drug

    TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

  • TAS-102Drug

    TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

  • RamucirumabDrug

    Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.

  • TAS-102Drug

    TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

  • BevacizumabDrug

    Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.

  • FluorouracilDrug

    Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.

  • CisplatinDrug

    Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.

  • AB154Drug

    AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.

  • FluorouracilDrug

    Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.

  • CarboplatinDrug

    Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.

  • CisplatinDrug

    Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.

  • CarboplatinDrug

    Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.

  • nab-PaclitaxelDrug

    Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

  • CisplatinDrug

    Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.

  • GemcitabineDrug

    Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.

  • nab-PaclitaxelDrug

    Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

  • GemcitabineDrug

    Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a (All cohorts except Cohort D-4, D-5 and D-9) : Percentage of participants who experience a Dose Limiting Toxicity (DLT)Time frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
  2. Phase 1a (Cohort D-4, D-5 and D-9) : Percentage of adverse events and treatment-related adverse events.Time frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
  3. Phase 1b (Cohort B-n, D-n and E-n) : Objective Response Rate (ORR)Time frame: Through completion of treatment (estimated up to be 11 months)
  4. Phase 1b (Cohort C-n): The 6-month PFS proportion by RECIST v1.1Time frame: Through completion of treatment (estimated up to be 11 months)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Aichi, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Chiba, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Ehime, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Hokkaido, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Kanagawa, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Osaka, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Shizuoka, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Tokyo, Japan · Recruiting

  • A site selected by Taiho Pharmaceutical Co., Ltd.

    Wakayama, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.